Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

Core Insights - Nexalin Technology, Inc. has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. to market and sell its Gen-2 SYNC device in Israel following regulatory approval from the Israeli Ministry of Health [1][2][3] Group 1: Agreement Details - The agreement allows Carmi Masha to manage sales, marketing, clinical education, importation, registration, and distribution of the SYNC device across various healthcare facilities in Israel [2] - The Gen-2 SYNC device is a non-invasive neurostimulation device designed to treat mental health disorders such as insomnia, depression, and anxiety [2][4] Group 2: Future Applications - Nexalin and Carmi Masha plan to explore future applications of the SYNC technology for conditions like PTSD, TBI, Alzheimer's disease, and other forms of dementia [2] Group 3: Company Strategy - The partnership is part of Nexalin's broader strategy to expand its global presence in high-value international markets and strengthen its footprint in the Middle East [3] - Nexalin's products are designed to be non-invasive and aim to provide relief for mental health issues using bioelectronic frequency-based medical technology [4]